A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer

INTRODUCTION: The 21-gene Recurrence Score(®) assay (Oncotype DX(®), Genomic Health, Inc.) is a validated predictor of recurrence risk/chemotherapy benefit in patients with estrogen receptor-positive (ER+) early-stage breast cancer treated with endocrine therapy. The Prosigna(®) assay (NanoString Te...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarado, Michael D., Prasad, Che, Rothney, Megan, Cherbavaz, Diana B., Sing, Amy P., Baehner, Frederick L., Svedman, Christer, Markopoulos, Christos J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679783/
https://www.ncbi.nlm.nih.gov/pubmed/26610383
http://dx.doi.org/10.1007/s12325-015-0269-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679783/
https://www.ncbi.nlm.nih.gov/pubmed/26610383
http://dx.doi.org/10.1007/s12325-015-0269-2

Ejemplares similares